TP53 and cancer: Similarly, STAG2 loss and TP53 mutations are other molecular biomarkers that have been shown to influence therapeutic responsiveness in various cancer types, including EWS (de Alava et al., 2000; Robles and Harris, 2010; Brohl et al., 2014).